News and communications

/News and communications

Neopharmed Gentili acquires Lormetazepam product portfolio to strengthen its neurology division

Milan, 1st March, 2022 – Neopharmed Gentili, an Italian pharmaceutical company controlled by Ardian in partnership with the Del Bono family, which has historic roots in its territory and is pursuing international growth, announced that it has entered into an agreement with Bayer for the acquisition of the rights in Italy and Japan to the historical brands Minias® and Noctamid® (Italy) and Evamyl® (Japan). Lormetazepam products are indicated in the short-term treatment of insomnia, in particular anxiety-induced insomnia.

Read more

ANNUAL REPORT SOCIAL 2020 NEOPHARMED GENTILI
SOCIAL MEDIA REPORT 2020 – TWITTER – INSTAGRAM – LINKEDIN

Read more

Press Release

PDF download